Business

Cipla Signs Licence Agreement with Novartis AG; Will Manufacture Type-2 Diabetes Medicine From 2026

From January 2026, Cipla Limited will be manufacturing Galvus and Galvus combination brands that are used in the treatment of type 2 diabetes. The drug maker signed a perpetual license arrangement. Cipla in an agreement with Switzerland-based Novartis Pharma AG, the company said in an exchange filing on Monday. Up to that point, the business would keep producing and selling goods under the Galvus name.

“This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category,” it added.

The fulfilment of certain prerequisite requirements is a requirement for the agreement.

Read More: India remains top destination for Russian Urals oil

Galvus is a well-known brand in the oral diabetic treatment market and among the top brands in the Dipeptidyl Peptidase-4 (DPP4) market. With reported sales of Rs 268 crore, Galvus has the potential to considerably expand Cipla’s portfolio in the diabetes care continuum market. (IQVIA MAT February 2023).

This agreement is anticipated to strengthen Cipla’s standing as one of the leading companies in the diabetes market in India. The reflection of this was clearly seen in how shares on Cipla’s performance on Monday post the announcement. Shares of Cipla closed Monday’s trading session on the BSE 1.02% higher at Rs 901.85 a share.

The oral medication Galvus belongs to the Dipeptidyl Peptidase-4 (DPP4) class. Its reported sales of 268 crores are projected to strengthen Cipla’s position in the diabetic market, according to the statement. Decreasing prices are to be expected in the coming year.

The anti-diabetic medication Vildagliptin’s brand name and trademark rights for Vysov and Vysov M (Vildagliptin + Metformin) were purchased by Cipla in December 2019 for the Indian market. Under the trade names Vysov and Vysov M, the business had been co-marketing Vildagliptin in accordance with Novartis.

Read More: Kotak Mahindra Bank’s FPI Shareholding Crosses 25% Mark, MSCI Weightage Likely to Surge

 

 

Malika Sahni

Recent Posts

AI & Surveillance Systems To Revolutionize Maha Kumbh 2025 Experience

The UP government is using AI, social media, and surveillance to ensure safety for 45…

20 minutes ago

Maha Kumbh 2025: Ultra-Modern Cruises To Become A Key Attraction For Devotees

The Yogi Adityanath-led UP government will introduce luxury cruises to transport devotees from Kashi to…

1 hour ago

Aam Aadmi Party Kicks Off ‘Revdi Par Charcha’ Campaign Ahead Of Delhi Elections

On Friday, AAP launched its 'Revdi Par Charcha' campaign to engage Delhi residents in the…

2 hours ago

Canada Denies Allegations Against Indian Leadership; Rejects Criminal Links

The Canadian govt addressed allegations linking Indian leaders to criminal activities, stating there is no…

2 hours ago

Delhi-NCR Faces ‘Very Poor’ Air Quality As Smog Engulfs Region

On Friday morning, Delhi-NCR's air quality was classified as 'very poor,' with a light haze…

3 hours ago

Indian Stock Market Rallies Despite Geopolitical Strains; Buoyed By Strong Domestic Sectors

The Indian stock market displayed resilience, opening on a positive note despite escalating geopolitical tensions…

5 hours ago